Methods and kits for determining von Willebrand factor activity in the absence of ristocetin
AssigneeSiemens Healthcare Diagnostics Products GmbH
InventorsHarald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
Life of this patent
Estimating the term…
Abstract
Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
Claims13
A method for determining von Willebrand factor (VWF) activity in a biological sample from a human patient, wherein the sample is mixed with purified glycoprotein Ib heavy chain (GPIbα) protein to give an assay mix, comprising the steps of:
- a) providing an isolated human GPIbα protein or functional fragment thereof associated with a particulate solid phase,
- wherein the isolated human GPIbα protein comprises mutations G233V and M239V relative to SEQ ID NO:1,
- wherein neither ristocetin nor botrocetin is added to the assay mix;
- and
- b) determining the VWF activity in the assay mix.
A method of measuring von Willebrand factor (VWF) activity in a biological sample from a human patient without using a platelet agglutination agonist, the method comprising the steps of:
- providing a solid-phase surface comprising immobilized purified human platelet glycoprotein Ibα (GPIbα) or a functional fragment thereof, wherein the immobilized human GPIbα or functional fragment thereof comprises mutations G233V and M239V relative to SEQ ID NO:1;
- contacting a biological sample from a patient with the surface, wherein the contacting is done without a platelet aggregation agonist;
- and detecting a complex of VWF and GPIbα.
Dependencies are inferred from the claim text.